menu
    • menu

    Company profile for AmMax Bio

    NEW Drugs in Dev: 3
    Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

    Virtual Booth

    Contact Supplier

    Lupin Manufacturing Solutions – delivering high-quality APIs & end-to-end CDMO services for faster, cost-effective drug development.

    Virtual Booth

    Contact Supplier

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    Egis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-2026-02-09

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    AmMax is a private clinical-stage biotech company founded in March 2020 to develop therapies under an exclusive worldwide license from Amgen, Inc. that leverage the diverse and critical roles played by the colony stimulating factor 1 receptor (CSF1R) signaling pathway for macrophage-driven diseases in multiple organ systems. AmMax has two clinical stage programs using AMB-05X, its proprietary CSF1R monoclonal antibody platf...
    AmMax is a private clinical-stage biotech company founded in March 2020 to develop therapies under an exclusive worldwide license from Amgen, Inc. that leverage the diverse and critical roles played by the colony stimulating factor 1 receptor (CSF1R) signaling pathway for macrophage-driven diseases in multiple organ systems. AmMax has two clinical stage programs using AMB-05X, its proprietary CSF1R monoclonal antibody platform. The company is enrolling patients in a Phase 2 clinical program for tenosynovial giant cell tumor (TGCT), and is preparing to initiate a Phase 2 clinical study in idiopathic pulmonary fibrosis (IPF) in early 2022.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    AmMax BioUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    Redwood City, CA
    Telephone
    Telephone
    1 (650) 787-3777
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.ammaxbio.com/home1380
    Linkedin
    Linkedin
    https://www.linkedin.com/company/ammax-bio-inc/
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Clinical Outsourcing

    Clinical Outsourcing

    Not Confirmed

    envelop Contact Supplier

    Clinical Outsourcing

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    AmMax Bio doses first subjects in Phase IIb trial of TGCT therapy
    AmMax Bio doses first subjects in Phase IIb trial of TGCT therapy

    30 Jan 2023

    // CLINICAL TRIALS ARENA

    https://www.clinicaltrialsarena.com/news/ammax-bio-subjects-trial-tgct/

    CLINICAL TRIALS ARENA
    30 Jan 2023
    Share Share
    AmMax Bio Announces First Patients Dosed in Phase 2b Study of AMB-05X for TGCT
    AmMax Bio Announces First Patients Dosed in Phase 2b Study of AMB-05X for TGCT

    30 Jan 2023

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2023/01/30/2597498/0/en/AmMax-Bio-Announces-First-Patients-Dosed-in-Phase-2b-Study-of-AMB-05X-for-the-Treatment-of-Tenosynovial-Giant-Cell-Tumor-TGCT.html

    GLOBENEWSWIRE
    30 Jan 2023
    Share Share
    AmMax Bio's AMB-05X Receives EMA PRIME Designation for the Treatment of TGCT
    AmMax Bio's AMB-05X Receives EMA PRIME Designation for the Treatment of TGCT

    19 Jan 2023

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2023/01/19/2592112/0/en/AmMax-Bio-s-AMB-05X-Receives-EMA-PRIME-Designation-for-the-Treatment-of-Tenosynovial-Giant-Cell-Tumor-TGCT.html

    GLOBENEWSWIRE
    19 Jan 2023
    Share Share
    AmMax Enters into an Agreement with Evopoint to License ADC
    AmMax Enters into an Agreement with Evopoint to License ADC

    09 Jan 2023

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2023/01/09/2585142/0/en/AmMax-Bio-Enters-into-an-Exclusive-Option-Agreement-with-Evopoint-Biosciences-to-License-a-Next-Generation-Antibody-Drug-Conjugate-ADC-for-the-Treatment-of-Solid-Tumors.html

    GLOBENEWSWIRE
    09 Jan 2023
    Share Share
    AmMax Bio Announces Oral Presentation of Phase 2 Data of AMB-05X
    AmMax Bio Announces Oral Presentation of Phase 2 Data of AMB-05X

    18 Nov 2022

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2022/11/18/2559064/0/en/AmMax-Bio-Announces-Oral-Presentation-of-Phase-2-Data-of-AMB-05X-for-the-Treatment-of-Tenosynovial-Giant-Cell-Tumor-TGCT-at-the-2022-CTOS-Annual-Meeting.html

    GLOBENEWSWIRE
    18 Nov 2022
    Share Share
    AmMax Bio Provides Update on AMB-05X Program for (TGCT)
    AmMax Bio Provides Update on AMB-05X Program for (TGCT)

    26 Sep 2022

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2022/09/26/2522462/0/en/AmMax-Bio-Provides-Update-on-AMB-05X-Program-for-Tenosynovial-Giant-Cell-Tumor-TGCT.html

    GLOBENEWSWIRE
    26 Sep 2022
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search